One To Watch

Skye Bioscience

A clinical-stage US biotechnology company developing nimacimab, a peripherally restricted CB1 inhibitor, for obesity, now pivoting toward a transformative merger with UK fibrosis specialist Redx Pharma.

Company Overview

A clinical-stage US biotechnology company developing nimacimab, a peripherally restricted CB1 inhibitor, for obesity, Skye Bioscience is navigating a pivotal corporate inflection point. Its lead Phase IIa asset delivered 22.3% total weight loss in combination with semaglutide, a result that validates the CB1 mechanism in the GLP-1 era. That data now underpins a partnering or divestment process, as Skye pivots to acquire UK-based Redx Pharma and relaunch as Fibrx Therapeutics.

Headquarters and Global Presence

The pending acquisition of Redx Pharma would add a UK operational footprint to the combined entity, which will be renamed Fibrx Therapeutics, Inc.

Founding and History

The August 2026 agreement to acquire Redx Pharma marks a strategic reversal, shifting the company's focus from metabolic disease to fibrosis.

Therapy Areas and Focus

Skye's primary focus has been obesity, targeting the endocannabinoid system as a complement to the dominant GLP-1 class rather than a competitor to it. CB1 receptors are implicated in appetite regulation, energy homeostasis, and metabolic function, offering a mechanistically distinct angle on weight management. The CBeyond program was designed explicitly to test whether CB1 inhibition can amplify GLP-1 efficacy, addressing the residual weight loss gap that even high-dose semaglutide leaves in many patients. With the Redx transaction, fibrotic disease becomes the forward strategic focus of the combined company.

Technology Platforms and Modalities

Nimacimab is a negative allosteric modulating antibody, a mechanistic design that distinguishes it from earlier orthosteric CB1 antagonists such as rimonabant, which caused central nervous system side effects severe enough to prompt market withdrawal. By restricting activity to peripheral tissues and modulating rather than fully blocking the receptor, the approach is designed to preserve metabolic benefit while eliminating the neuropsychiatric liability. The Phase IIa data reported no nimacimab-associated neuropsychiatric adverse events, a clean safety signal that is commercially important given rimonabant's history.

Key Pipeline and Programs

Nimacimab is the company's sole disclosed clinical asset. In the Phase IIa CBeyond proof-of-concept study, nimacimab was evaluated both as monotherapy and in combination with semaglutide 2.4 mg. Interim 52-week combination data for nimacimab 200 mg plus semaglutide 2.4 mg showed 22.3% total weight loss with a clean safety profile. Full topline data from the CBeyond Phase IIa extension study are expected in Q3 2026, with topline data from the CBeyond Expansion Study expected in Q4 2026. The program had been positioned for Phase IIb GLP-1 combination development, though the Redx transaction places the nimacimab asset under evaluation for divestment or partnering rather than continued internal advancement. Redx Pharma's lead asset, RXC008, targets fibrosis and will anchor the pipeline of the combined Fibrx Therapeutics entity.

Recent Developments

On August 14, 2026, Skye agreed to acquire UK-based Redx Pharma via a UK scheme of arrangement, with the deal backed by approximately $125 million in concurrent financings. The combined company will be renamed Fibrx Therapeutics, Inc., led by the Redx management team and board, and is expected to close in Q4 2026. The topline CBeyond Phase IIa data release and the Redx deal together represent the two defining events of 2026 for Skye.

Key Personnel

Punit Dhillon serves as President and Chief Executive Officer of Skye Bioscience, having led the company's entry into obesity and the subsequent Redx transaction. The combined Fibrx Therapeutics entity will be led by the Redx management team and board post-close.

Strategic Partnerships

The most consequential strategic move is the agreed acquisition of Redx Pharma, a UK-based, privately held clinical-stage biotechnology company focused on small molecule medicines for fibrotic disease. The transaction, announced August 14, 2026, is structured as a UK scheme of arrangement and is expected to close in Q4 2026, supported by approximately $125 million in concurrent financings. Nimacimab, the core asset Skye built its obesity thesis around, is now being evaluated for external divestment or partnering as part of the post-merger portfolio realignment.

FAQ Section

The 22.3% total weight loss figure from the nimacimab-semaglutide combination is clinically meaningful, but developing a GLP-1 adjunct through Phase IIb and beyond requires substantial capital and commercial infrastructure. The Redx transaction gives Skye access to a fibrosis portfolio with its own financing and an experienced management team, and the company's leadership appears to have judged that nimacimab's value is better realized through a partner than through continued internal spending. The asset has not been abandoned; divestment or out-licensing remains on the table.

Rimonabant, the first CB1 antagonist approved for obesity, was withdrawn due to severe neuropsychiatric side effects including depression and suicidality, caused by central CB1 blockade. The endocannabinoid system still represents a validated metabolic target, and peripherally restricted CB1 modulation avoids the CNS exposure that doomed the earlier drug class. Nimacimab's negative allosteric mechanism further reduces receptor engagement compared with full orthosteric blockade, and the absence of neuropsychiatric adverse events in CBeyond is the clinical proof point the field needed.

Nimacimab is a peripherally restricted antibody, meaning its large molecular size limits central nervous system penetration, avoiding the brain CB1 activity responsible for rimonabant's psychiatric risks. It acts as a negative allosteric modulator rather than a competitive antagonist, tuning down receptor activity rather than fully blocking it, which may preserve physiological signaling that orthosteric blockade eliminates. This combination of peripheral restriction and allosteric modulation is the mechanistic argument for a cleaner safety profile at therapeutically meaningful doses.

The CBeyond proof-of-concept study tested nimacimab as monotherapy and in combination with semaglutide 2.4 mg. The combination arm delivered 22.3% total weight loss at 52 weeks for nimacimab 200 mg plus semaglutide, with a clean safety profile and no nimacimab-associated neuropsychiatric adverse events. Full topline data from the Phase IIa extension are expected in Q3 2026, and expansion cohort topline data in Q4 2026, providing a more complete efficacy and safety picture before any Phase IIb decisions are finalized.

Post-merger, Fibrx Therapeutics will be focused on fibrotic disease, anchored by Redx Pharma's lead asset RXC008. Redx is a UK-based, privately held clinical-stage company specializing in novel small molecule targeted medicines for fibrosis, a field with significant unmet need and growing pharmaceutical interest. Nimacimab and Skye's obesity work are expected to exit the portfolio through divestment or partnering, leaving Fibrx as a fibrosis-focused entity.

Skye has completed Phase IIa in obesity and delivered interim combination data, placing nimacimab at a pre-Phase IIb inflection point where it would normally require a major capital commitment to advance. Instead, the company has agreed a transformative acquisition expected to close in Q4 2026, after which it will operate as Fibrx Therapeutics under Redx's management. The Q3 and Q4 2026 data readouts from CBeyond extension and expansion cohorts are the remaining near-term milestones for the Skye-era obesity program.

The next six months will determine whether Skye's two strategic threads resolve cleanly.

Want to Update your Company's Profile?